The time is now for Medical Affairs
On September 30th, 2013, a panel of Japan’s Health and Welfare Ministry issued an interim report on the manipulation of clinical research data on Diovan, a blood pressure-lowering drug, for Novartis Pharma. Aftershocks of the recent Diovan scandal have reverberated around Japan’s pharmaceutical industry. Quite expectedly, medical affairs (MA) will require strict compliance in medical and sales and marketing activities.
The environment on evidence generation through investigator-initiated trials (IITs) is fast changing. In the past, companies supported large-scale and local IITs by providing them with financial and administrative support. A senior Medical Director that we spoke to warned, “that the local studies may be the most dangerous as they are not always conducted according to GCP and are more related to commercial objectives, aligned with the importance of the centers or the power of the principal investigator. This practice used to exist everywhere and has long stopped in Europe. It still exists with some companies but I believe that it will stop in the near future”.
Medical affairs will need to lead initiatives to allay concerns of the industry by ensuring the independence of study organizations from funders and improving the quality of clinical studies through compliance with ICH-GCP. IITs will require adherence to standards of good clinical practice (GCP) set by the International Conference on Harmonization (ICH). Furthermore, companies will increase focus on programs with high transparency.
Most companies have two types of scientific teams: one for development and another for medical affairs. Development defines the scientific direction and early-stage development, as well as includes clinical trial runs, whereas medical affairs provide scientific support for late-stage development and post market support. In small companies, the same team may be responsible for both types of activities.
Medical affairs and medical liaison function alongside marketing to provide technical support to both internal teams and external customers. Medical liaison teams include field-based medical information specialists who provide in-depth drug and disease information to health providers. Both medical affairs and medical liaison teams provide information services to educate department employees and thus ensure that consumer questions are addressed, as well as disseminate data to health care providers in the community. Medical affairs teams also formulate publications plans and report key trial results to the PMDA, in scientific meetings, and through journal articles.
Social pressure to ensure research independence and publication of relevant data that benefit patients has increased. The goals are to increase the number of publications and improve the standard of medical science in Japan. Ultimately, the strength and performance of medical affairs departments will have a direct correlation to the number and quality of highly ethical scientific publications.
The crisis initiated by the Diovan scandal may prove to be the catalyst to improve the quality of educational and promotional materials (medical affairs teams prepare scientific information for marketing purposes) and to deepen relationships with professional associations, patient support groups, and advocacy groups.
The race to attract top medical affairs and medical liaison talents has intensified. More important, the pressure has increased on medical affairs and medical liaison to ensure that pre-promotion, off-label promotion of products are and not carried out and along with any unscientific bias promotion or prescription inducible clinical trial and that outside speakers do not act as a company’s operative or champion.
MA is playing a more critical role than ever; a leading European MA Director explained that “Medical Affairs should really function as the emergency brake for the shuttle that runs between the commercial organization and the R&D organization. Some companies have the MA organization residing in either one of these larger functional areas in either a matrix organization or adjacent functional area. The “brake” function comes into play, when the commercial organization in ostensibly “innovative” proposal is running a high risk of inflicting grievous harm to the reputation of a company in the post marketing space or the R&D organization is pursuing non-value added activities that have little or no commercial POS (probability of success), then MA needs to step in and speak to the science and provide supportive data to bolster their position or assessment. They are critical to prevent nefarious activities in both the development space as well as the post marketing space and hence prevent either loss of value (EPS) and subsequently investors’ confidence or loss of trust (from a tarnished reputation) due to unethical behavior”.
One of Asia’s leading Clinical Directors prophesied, “the future is bright for MA to become the star in the data generation, data recognition, data interpretation and analytics, arena as they pursue and the only real metric that matters in this industry, “speed to market” of high quality, safe and effective medicines. The future beckons with opportunity and the company which can capitalize on this will reap fortunes even for niche market and unmet medical needs drugs, that usually only come with blockbuster drugs. The formula is simple DATA → Information → Knowledge → Wisdom. The real commercial differential for success is not in Pharma knowledge but in Pharma wisdom. MA can become the star in this role rather than the cameo appearance it currently makes in this arena”.
The successful MA teams will be able to find the proverbial needle (data) in the hay stack while being in compliance with GCP guidelines. No one can predict the future but one thing is clear, MA is becoming one of the most critical functions at pharmaceutical companies.
In my home country of Australia, there is a famous type of candy called “Minties”. The company that produces M
I attended a wedding in Hiroshima recently and one of the guests asked me about my line of business in Tokyo. “Ex
“Leadership is taken, not given,” a Novartis director revealed recently. It is one thing to bestow the title of
On Christmas Day 2015, twenty-four-year-old Ms. Matsuri Takahashi, a graduate of the University of Tokyo and employ
An American Pharma company had spent many months and millions of yen retaining one of the world’s leading recruit
It was a cold and windy December night in 2002 when I met a sales director from Pfizer at my office in Aoyama, Toky